Strona główna > News > Ngs panels make their world debut
News
Print
NGS Panels Make Their World Debut    

Genomed presented its offer at the 2013 BIO International Convention, implementing its strategy of brand development on international markets and of promoting overseas sales.

Bioconvention

The USA-based BIO International Convention is one of the world’s major events for the biotechnological industry, annually attracting exhibitors from over 65 countries along with tens of thousands of visitors. The event aims at bringing together the worlds of business and science. This year’s conference - its anniversary, twentieth edition - was held in Chicago, from April 22 to 25. The leading subjects were the development of personalized medicine, including the genetic diagnostics accompanying the administration of drugs; issues pertaining to patent protection in biotechnology; and the diagnostics and treatment of orphan diseases. During the fair, Genomed promoted its most recent products – diagnostic panels carried out by means of Next Generation Sequencing (NGS). Genomed was the first company in Poland to introduce a diagnostic panel for Neurofibromatosis type I which uses NGS. The test identifies approximately 90% of all the known mutations occurring in the NF1 gene. In the nearest future, the offer is going to expand by further diagnostic panels – an ophthalmological one and others, for ataxia, hypercholesterolemia, as well as for breast and ovarian cancer.
“Adopting this ultramodern technology has enabled us to read far more information, within a shorter period of time and at a lower cost per patient than when using traditional methods of genetic diagnostics,” says Anna Boguszewska-Chachulska, PhD, the company’s board member who attended the conference.

The company’s offer enjoyed considerable interest at the BIO International Convention among both visitors and exhibitors from all over the world. During the fair, more than 200 people visited the Genomed stand, and a few dozen business meetings were held with representatives of foreign companies and institutions.

The company’s participation in fairs is co-financed from the European Regional Development Fund, within the framework of the Innovative Economy Operational Programme 2007-2013, submeasure 6.5.2. Also as part of the project, the company is planning to participate in two more industry shows of international consequence this year – Bioforum 2013 in Budapest and BIOTECHNICA in Hanover.  

Marta Domańska


download pdf file